Oxford BioMedica's shares fell 15% after Novartis and Bristol Myers Squibb paused enrollment in their autoimmune CAR-T therapy trials due to safety concerns, including patient deaths and inflammatory events. Despite this, broker Panmure Liberum maintains a 'buy' rating, noting that autoimmune programs represent only 13% of Oxford BioMedica's pipeline, limiting the impact. The broker believes the share price decline is excessive given the company's valuation and pipeline diversity, and expects any short-term effects to be manageable within current guidance. Interim results are expected on September 22.
Nvidia has returned a record $26 billion to its shareholders after increasing its dividend by an extraordinary 2,400%. This massive payout highlights the company's strong financial position and commitment to rewarding investors. The significant divid...
GoMining Academy has introduced a free, beginner-friendly course covering blockchain technology and cryptocurrency fundamentals. The course includes eight lessons with about 80 minutes of video, explaining key concepts like decentralized networks, Bi...
Bitcoin's price dropped below $77,000 due to renewed U.S.-Iran strikes but quickly rebounded to around $78,000. Despite this recovery, Bitcoin remains below last week's peak near $81,400. The price movement reflects ongoing geopolitical tensions affe...
Dell Technologies reported a significant surge in AI-related orders, with its AI backlog reaching $95 billion and Q2 orders hitting $60.9 billion compared to $16.4 billion in revenue. The company expects AI server revenue to triple to $74 billion by ...
Nvidia is forecasted to maintain its stock price above $200 by September 30, with an average predicted price of $215.50, driven by robust demand for AI technology. The company reported impressive Q2 fiscal 2027 results, including a 106% revenue incre...
